Skip to content

Trial Summary

First-in-human study to assess safety, tolerability, PK, and preliminary activity of PF-07284890 as a single agent and in combination with binimetinib in participants with BRAF V600-mutated advanced solid tumor malignancies with and without brain involvement.



ACTRN/NCT /ethics:


Scientific title:

A two-part, phase 1a/b, open-label, multicenter trial evaluating pharmacokinetics, safety and efficacy of pf 07284890 (arry 461) in participants with braf v600 mutant solid tumors with and without brain involvement

Sponsor / Cooperative group:


Trial & Patient Characteristics

Cancer TypeBrain & central nervous system, Lung & mesothelioma, Melanoma & other skin
Trial TypeTreatment
PhasePhase I
Age Range18 years and older
Tumour Stream -
Cancer StageAll stages
Anticipated Start Date2021-01-08
Anticipated End Date2023-09-30

Participating Hospitals

HospitalRoyal Adelaide Hospital
Clinical Trial CoordinatorAnne Milton
Phone08 7074 2342
Principal InvestigatorDr Hsiang Tan
Recruitment StatusRecruiting